Antitumor effects in vitro and in vivo and mechanisms of protection against melanoma B16F10-Nex2 cells by fastuosain, a cysteine proteinase from Bromelia fastuosa

Neoplasia

Volumn 9, Issue 9, 2007, Pages 723-733

  Guimarães Ferreira, Carla A ^a   Rodrigues, Elaine G ^a,d   Mortara, Renato A ^a,d   Cabral, Hamilton ^b   Serrano, Fabiana A ^a   Ribeiro dos Santos, Ricardo ^c,d   Travassos, Luiz R ^a,d  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

^d Fellow of the National Research Council   (Brazil)

Author keywords

B16F10 Nex2 tumor cells; Bromelain; Cathepsins B L; Fastuosain; Protective antibodies

Indexed keywords

B 4882; BROMELAIN; CATHEPSIN B; CATHEPSIN L; FASTUOSAIN; GREEN FLUORESCENT PROTEIN; HERBACEOUS AGENT; HERMES ANTIGEN; MATRIGEL; PAPAIN; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BROMELIA FASTUOSA; CELL COUNT; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; LUNG METASTASIS; LYMPHOCYTE; MALE; MEDICINAL PLANT; MELANOMA; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 34948835723     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07427     Document Type: Article

References (31)

1. Cabral H, Leopoldino AM, Tajara EH, Greene LJ, Faca VM, Mateus RP, Ceron CR, Judice WAD, Juliano L, and Bonilla-Rodriguez GO (2006). Preliminary functional characterization, cloning and primary sequence of Fastuosain, a cysteine peptidase isolated from fruits of Bromelia fastuosa. Protein Pept Lett 13, 83-89.
2. Maurer HR (2001). Bromelain: biochemistry, pharmacology and medical use. Cell Mol Life Sci 58, 1234-1245.
3. Metzig C, Grabowska E, Eckert K, and Maurer HR (1999). Bromelain proteases reduce human platelet aggregation in vitro, adhesion to bovine endothelial cells and thrombus formation in rat vessels in vivo. In Vivo 13, 7-12.
4. Tysnes BB, Maurer HR, Porwol T, Probst B, Bjerkvig R, and Hoover F (2001). Bromelain reversibly inhibits invasive properties of glioma cells. Neoplasia 3, 469-479.
5. Hale LP, Fitzhugh DJ, and Staats HF (2006). Oral immunogenicity of the plant proteinase bromelain. Int Immunopharmacol 6, 2038-2046.
6. Bellelli A, Mattioni M, Rusconi V, Sezzi ML, and Bellellei L (1990). Inhibition of tumor growth, invasion and metastasis in papain-immunized mice. Invasion Metastasis 10, 142-169.
7. Wald M, Zavadova E, Pouckova P, Zadinova M, and Boubelik M (1998). Polyenzyme preparation Wobe-Mugos inhibits growth of solid tumors and development of experimental metastases in mice. Life Sci 62, PL43-PL48.
8. Barros HC, Verbisck NV, DaSilva S, Araguth MF, and Mortara RA (1997). Distribution of epitopes of Trypanosoma cruzi amastigotes during the intracellular life cycle within mammalian cells. J Eukaryot Microbiol 44, 332-344.
9. Grabowska E, Eckert K, Fichtner I, SchulzeForster K, and Maurer HR (1997). Bromelain proteases suppress growth, invasion and lung metastasis of B16F10 mouse melanoma cells. Int J Oncol 11, 243-248.
10. Hale LP and Haynes BF (1992). Bromelain treatment of human T cells removes CD44, CD45RA, E2/MIC2, CD6, CD7, CD8, and Leu 8/LAM1 surface molecules and markedly enhances CD2-mediated T cell activation. J Immunol 149, 3809-3816.
11. Hale LP, Greer PK, and Sempowski GD (2002). Bromelain treatment alters leukocyte expression of cell surface molecules involved in cellular adhesion and activation. Clin Immunol 104, 183-190.
12. Sloane BF, Rozhin J, Krepela E, Zlegler G, and Sameni M (1991). The malignant phenotype and cysteine proteinases. Biomed Biochim Acta 50, 549-554.
13. Kageshita T, Yoshii A, Kimura T, Maruo K, Ono T, and Himeno M (1995). Biochemical and immunohistochemical analysis of cathepsin B, H, L and D in human melanotic tumors. Arch Dermatol Res 287, 266-272.
14. Frohlich E, Schlagenhauff B, Mohrle M, Weber E, Klessen C, and Rassner G (2001). Activity, expression, and transcription rate of the cathepsins B, D, H and L in cutaneous malignant melanoma. Cancer 91, 972-982.
15. Stabuc B, Mrevlje Z, Markovic J, and Stabuc-Silih M (2006). Expression and prognostic significance of Cathepsin L in early cutaneous malignant melanoma. Neoplasma 53, 259-262.
16. Server N, Filipic M, Brzin J, and Lah TT (2002). Effect of cysteine proteinase inhibitors on murine B16 melanoma cell invasion in vitro. Biol Chem 383, 839-842.
17. Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, Hanahan D, and Joyce JA (2006). Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 20, 543-556.
18. Wald M, Olejar T, Pouckova P, and Zadinova M (1998). Proteinases reduce metastatic dissemination and increase survival time in C57BL/6 mice with the Lewis lung carcinoma. Life Sci 63, PL237-PL243.
19. Wald M, Olejar T, Sebkova V, Zadinova M, Boubelik M, and Pouckova P (2001). Mixture of trypsin, chymotrypsin and papain reduces formation of metastases and extends survival time of C57BL/6 mice with syngeneic melanoma B16. Cancer Chemother Pharmacol 47, S16-S22.
20. Harrach T, Gebauer F, Eckert K, Kunke R, and Maurer HR (1994). Bromelain proteinases modulate the CD44 expression on human Molt 4/8 leukemia and SkMel-28 melanoma cells in vitro. Int J Oncol 5, 485-488.
21. Eckert K, Grabowska E, Stange R, Schneider U, Eschmann K, and Maurer HR (1999). Effects of oral bromelain administration on the impaired immunocytotoxicity of mononuclear cells from mammary tumor patients. Oncol Rep 6, 1191-1199.
22. Bader T and Wietzerbin J (1994). Modulation of murine and human interferon-gamma receptor expression by their ligands or phorbol ester. Cytokine 6, 70-78.
23. Engwerda CR, Andrew D, Murphy M, and Mynott T (2001). Bromelain activates murine macrophages and natural killer cells in vitro. Cell Immunol 210, 5-10.
24. Rodrigues EG, Garofalo AS, and Travassos LR (2002). Endogenous accumulation of IFN-gamma in IFN-gamma-R(-/-) mice increases resistance to B16F10-Nex2 murine melanoma: a model for direct IFN-gamma anti-tumor cytotoxicity in vitro and in vivo. Cytokines Cell Mol Ther 7, 107-116.
25. Hicks AM, Riedlinger G, Willingham MC, Alexander-Miller MA, Von Kap-Herr C, Pettenati MJ, Sanders AM, Weir HM, Du W, Kim J, et al. (2006). Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proc Natl Acad Sci USA 103, 7753-7758.
26. Qian F, Frankfater A, Steiner DF, Bajkowski AS, and Chan SJ (1991). Characterization of multiple cathepsin B mRNAs in murine B16a melanoma. Anticancer Res 11, 1445-1451.
27. Moin K, Cao L, Day NA, Koblinski JE, and Sloane BF (1998). Tumor cell membrane cathepsin B. Biol Chem 379, 1093-1099.
28. Freitas ZF, Rodrigues EG, Oliveira V, Carmona AK, and Travassos LR (2004). Melanoma heterogeneity: differential, invasive, metastatic properties and profiles of cathepsin B, D and L activities in subclones of the B16F10-NEX2 cell line. Melanoma Res 14, 333-344.
29. Frosch BA, Berquin I, Emmert-Buck MR, Moin K, and Sloane BF (1999). Molecular regulation, membrane association and secretion of tumor cathepsin B. APMIS 107, 28-37.
30. Kobayashi H, Moniwa N, Sugimura M, Shinohara H, Ohi H, and Terao T (1993). Effects of membrane-associated cathepsin B on the activation of receptor-bound prourokinase and subsequent invasion of reconstituted basement membranes. Biochim Biophys Acta 1178, 55-62.
31. Cavallo-Medved D, Mai J, Dosescu J, Sameni M, and Sloane BF (2005). Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells. J Cell Sci 118, 1493-1503.